Gary Fanger, president and chief executive officer of Rise Therapeutics, stated, “With our third drug now in clinical development, we have the opportunity with R-5280 to control another devastating disease using an oral immunotherapy approach.”

Type 1 diabetes is a chronic autoimmune condition in which the pancreas produces little to no insulin. Without enough insulin, blood sugar levels can become dangerously high. Type 1 diabetes typically develops in childhood or adolescence and patients require lifelong insulin therapy to manage their blood sugar levels and prevent complications. Approximately 1.6 million people in the United States are affected by type 1 diabetes, and around 40,000 people receive a new diagnosis of type 1 diabetes in the U.S. each year.